The company has developed several proprietary immuno-oncology therapeutic platforms, including TriTETM, CCNKTM, and CCMφTM. The pipeline antibodies developed based on these platforms could stimulate or modulate immune cells to fight against cancer.
CytoCares is a pioneer in utilizing of “Two-Signal” system of T cell activation in the multi-specific antibody design and has expanded its expertise from hematologic malignancies to solid tumor.
Trispecific T-cell Engager (TriTE) offering full activation signal to T cell through co-engagement of TCR/CD3 and co-stimulatory receptor
NK activation receptor agonists or inhibitory receptor antagonists for effective tumor killing
Marcrophage revitalize agents to enhance innate as well as adaptive immunity for cancer treatment
2023年8月7日，靠谱棋牌网站生物在中国医学科学院血液病医院进行的CC312 I期首次人体试验已经完成首例患者入组及首次给药，从目前首例患者的临床安全性检测数据来看，首例患者耐受良好，没有药物相关的不良事件发生。
靠谱棋牌网站生物有幸受邀参加了7月14日下午的IBI EXPO 2023 国际生物创新药产业大会会议分论坛“第三届生物创新药产业投资论坛“，与各位医药业界同行共同探讨生物药产业发展的现在与未来。
2023年7月7日，靠谱棋牌网站生物与中国医学科学院血液病医院（中国医学科学院血液学研究所）合作的“一项评价CC312在复发/难治性CD19阳性B细胞恶性血液肿瘤成年患者的安全耐受性、药代动力学（PK）、药效动力学（PD）、免疫原性及初步抗肿瘤活性的多中心I期临床研究”启动会顺利召开。
